Home > Insider Trading > Filing (0001493152-24-050675)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1855485	Calidi Biotherapeutics Inc.	CLDI	Biological Products, (No Disgnostic Substances) (2836)	862967193

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1990674	Allan Camaisa	C/O Calidi Biotherapeutics, Inc. 4475 Executive Drive, Suite 200 San Diego, CA 92121	Ceo And Chairman Of The Board	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2024-12-17	10,000	$1.62	66,712	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct

Footnotes

The sales reported in this Form 4 were effected for tax planning purposes. The reporting person undertakes to provide full information regarding the number of shares and prices at which the transactions were effected upon request of the SEC staff, the Issuer or a security holder of the Issuer.
Includes 6,557 shares of Common Stock directly held by Allan Camaisa. Does not include (i) 14,000 shares of Common Stock issuable upon exercise of options held by Mr. Camaisa under the 2023 Equity Plan, (ii) 6,445 shares of Common Stock issuable upon exercise of options held by Mr. Camaisa under the 2019 Equity Plan, (iii) 46,972 shares of Common Stock issuable upon exercise of warrants within sixty (60) days held by Mr. Camaisa, (iv) 70,760 shares of Common Stock issuable upon exercise of options held by AJC Capital, LLC ("AJC"), (v) 203,954 shares of Common Stock issuable upon exercise of options held by AJC, (vi) 281,513 shares of Common Stock held by AJC, and (vii) 608,383 shares of Common Stock held by Jamir Trust. Mr. Camaisa is the sole managing member and owner of AJC and the sole trustee of Jamir Trust; as such, Mr. Camaisa may be deemed to have beneficial ownership of the Common Stock held by AJC and Jamir Trust.